COI notes: Dr. Dhakal has served on the advisory board of Takeda, Amgen, and Jansen. He
has received honorarium from Celgene. Mehdi Hamadani reports Research …

Three reports address the protection of the vulnerable population of patients with
hematologic malignancies in the face of the ongoing COVID pandemic. The reports suggest …

Recipients after hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor
T-cell (CAR-T) therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 …

ABSTRACT Coronavirus disease 2019 (COVID-19), a respiratory illness caused by the
novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a …

We read with great interest the paper by He et al.[1] on the outcome of COVID-19 infection in
hematological malignancy patients. This study was one of the first to report the outcome in …

Three reports address the protection of the vulnerable population of patients with
hematologic malignancies in the face of the ongoing COVID pandemic. The reports suggest …

At the time of this writing, the World Health Organization has upgraded the global risk of the
Coronavirus Disease 2019 (COVID-19) outbreak to 'very high'. Since the first reports less …

The long-term clinical efficacy of SARS-CoV-2 vaccines according to antibody response in
immunosuppressed patients such as hematological patients has been little explored. A …

Background Haematopoietic stem-cell transplantation (HSCT) recipients are considered at
high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status …

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment
for a wide range of hematological diseases but is still associated with significant infection …